Download PDF
Klin Monbl Augenheilkd 2017; 234(05): 670-673
DOI: 10.1055/s-0043-107807
Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Neue adjuvante Therapien beim okulären Melanom

Novel Adjuvant Therapy for Ocular Melanoma
Jacobus J. Bosch
1   Medizinische Klinik 5, Hämatologie und internistische Onkologie, Universitatsklinikum Erlangen
,
Ludwig M. Heindl
2   Zentrum für Augenheilkunde, Universität zu Köln
› Author Affiliations
Further Information

Publication History

eingereicht 25 January 2017

akzeptiert 27 March 2017

Publication Date:
15 May 2017 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Hintergrund Das maligne Melanom ist der häufigste und bösartigste Tumor des Auges im Erwachsenenalter. Trotz erfolgreicher Behandlung des Primärtumors ist eine wirksame Therapie des metastasierenden konjunktivalen und uvealen Melanoms derzeit nicht bekannt. Die melanomassoziierte Lymphangiogenese sowie die Immunzellinfiltration sind wichtige Metastasierungsmechanismen und bieten potenzielle Ansatzpunkte, um eine neue adjuvante Therapie beim okulären Melanom zu etablieren.

Projektbeschreibung Die vorliegende Arbeit gibt einen kompakten Überblick über den aktuellen Wissensstand von Klinik und Forschung zum Thema der tumorassoziierten Lymphangiogenese und deren medikamentöser Hemmung sowie der Aktivierung des melanomassoziierten Immunzellinfiltrats mittels passiver oder aktiver Immuntherapie beim Melanom am Auge. Insbesondere werden die Forschungsansätze und wichtigsten Resultate unserer bisherigen Arbeiten sowie unserer aktuellen translationalen Forschung zu diesem Thema im Teilprojekt 4 „Melanom am Auge“ der Forschergruppe FOR 2240 „(Lymph)Angiogenesis and Cellular Immunity in Inflammatory Diseases of the Eye“ zusammengefasst.

Schlussfolgerungen Die Hemmung der inflammatorischen Lymphangiogenese und die Modulation von Immunantworten könnten einen vielversprechenden Ansatz beim malignen Melanom am Auge darstellen, um das Überleben dieser Patienten zu verlängern.

Abstract

Background Malignant melanoma is the most common cancer of the eye in adults that originates either in the intra-ocular uveal tract or extra-ocular conjunctiva. Although the primary tumor can be treated successfully, no effective therapy for both metastatic conjunctival and uveal melanoma currently exits. Tumor-associated lymphangiogenesis and immune cell infiltration play a pivotal role in the development and therapeutic targeting of metastases.

Project description Here, we provide an overview of current translational research on lymphangiogenesis and its therapeutic inhibition as well as modulation of immune cell infiltration by passive and active immunotherapy in melanoma of the eye. Specifically, our previous and ongoing work on lymphangiogenesis and immune cells in ocular melanoma within the clinical research unit FOR 2240 “(Lymph)Angiogenesis and Cellular Immunity in Inflammatory Diseases of the Eye” is summarized.

Conclusions Translational research on the modulation of tumor-associated lymphangiogenesis and immune cell infiltration could provide novel targets for adjuvant therapy in melanoma of the eye.

Schlüsselwörter

Bindehaut - Chorioidea - okuläre Tumoren - Pathologie

Key words

conjunctiva - choroid - ocular tumors - pathology
 

  • Literatur

  • 1 Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye 2017; 31: 241-277
    CrossrefPubMedGoogle Scholar
  • 2 Bornfeld N, Bechrakis NE. Perspectives in ocular oncology. Klin Monatsbl Augenheilkd 2010; 227: 529
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Augsburger JJ, Corrêa ZM, Shaikh AH. Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol 2009; 148: 119-127
    CrossrefPubMedGoogle Scholar
  • 4 Shildkrot Y, Wilson MW. Conjunctival melanoma: pitfalls and dilemmas in management. Curr Opin Ophthalmol 2010; 21: 380-386
    CrossrefPubMedGoogle Scholar
  • 5 Heindl LM, Lotter M, Strnad V. et al. Hochdosisbrachytherapie des malignen Aderhaut- und Ziliarkörpermelanoms mit 106 Ruthenium. Eine klinisch-pathologische Studie. Ophthalmologe 2007; 104: 149-157
    CrossrefPubMedGoogle Scholar
  • 6 Blum ES, Yang J, Komatsubara KM. et al. Clinical management of uveal and conjunctival melanoma. Oncology 2016; 30: 29-32 34–43, 48
    PubMedGoogle Scholar
  • 7 Kujala E, Kivelä T. Tumor, node, metastasis classification of malignant ciliary body and choroidal melanoma evaluation of the 6th edition and future directions. Ophthalmology 2005; 112: 1135-1144
    CrossrefPubMedGoogle Scholar
  • 8 Dithmar S, Diaz CE, Grossniklaus HE. Intraocular melanoma spread to regional lymph nodes: report of two cases. Retina 2000; 20: 76-79
    CrossrefPubMedGoogle Scholar
  • 9 Patel SP. Latest developments in the biology and management of uveal melanoma. Curr Oncol Rep 2013; 15: 509-516
    CrossrefPubMedGoogle Scholar
  • 10 Leyvraz S, Keilholz U. Ocular melanoma: whatʼs new?. Curr Opin Oncol 2012; 24: 162-169
    CrossrefPubMedGoogle Scholar
  • 11 Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol 2003; 3: 879-889
    CrossrefPubMedGoogle Scholar
  • 12 Niederkorn JY. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat Immunol 2006; 7: 354-359
    CrossrefPubMedGoogle Scholar
  • 13 Heindl LM, Schrödl F, Lütjen-Drecoll E. et al. Ciliary body lymphangiogenesis. Ophthalmology 2013; 120: e41-e42
    CrossrefPubMedGoogle Scholar
  • 14 Schrödl F, Kaser-Eichberger A, Trost A. et al. Lymphatic markers in the adult human choroid. Invest Ophthalmol Vis Sci 2015; 56: 7406-7416
    CrossrefPubMedGoogle Scholar
  • 15 Kaser-Eichberger A, Schrödl F, Trost A. et al. Topography of lymphatic markers in human iris and ciliary body. Invest Ophthalmol Vis Sci 2015; 56: 4943-4953
    CrossrefPubMedGoogle Scholar
  • 16 Schlereth SL, Neuser B, Herwig MC. et al. Absence of lymphatic vessels in the developing human sclera. Exp Eye Res 2014; 125: 203-209
    CrossrefPubMedGoogle Scholar
  • 17 Zimmermann P, Dietrich T, Bock F. et al. Tumour-associated lymphangiogenesis in conjunctival malignant melanoma. Br J Ophthalmol 2009; 93: 1529-1534
    CrossrefPubMedGoogle Scholar
  • 18 Heindl LM, Hofmann TN, Knorr HL. et al. Intraocular lymphangiogenesis in malignant melanomas of the ciliary body with extraocular extension. Invest Ophthalmol Vis Sci 2009; 50: 1988-1995
    CrossrefPubMedGoogle Scholar
  • 19 Heindl LM, Hofmann TN, Adler W. et al. Intraocular tumor-associated lymphangiogenesis a novel prognostic factor for ciliary body melanomas with extraocular extension?. Ophthalmology 2010; 117: 334-342
    CrossrefPubMedGoogle Scholar
  • 20 Heindl LM, Hofmann TN, Schrödl F. et al. Intraocular lymphatics in ciliary body melanomas with extraocular extension: functional for lymphatic spread?. Arch Ophthalmol 2010; 128: 1001-1008
    CrossrefPubMedGoogle Scholar
  • 21 Heindl LM, Hofmann-Rummelt C, Adler W. et al. Tumor-associated lymphangiogenesis in the development of conjunctival melanoma. Invest Ophthalmol Vis Sci 2011; 52: 7074-7083
    CrossrefPubMedGoogle Scholar
  • 22 Heindl LM, Hofmann-Rummelt C, Adler W. et al. Prognostic significance of tumor-associated lymphangiogenesis in malignant melanomas of the conjunctiva. Ophthalmology 2011; 118: 2351-2360
    CrossrefPubMedGoogle Scholar
  • 23 Koch KR, Refaian N, Hos D. et al. Autocrine impact of VEGF-A on uveal melanoma cells. Invest Ophthalmol Vis Sci 2014; 55: 2697-2704
    CrossrefPubMedGoogle Scholar
  • 24 Refaian N, Schlereth SL, Koch KR. et al. Comparing the hem- and lymphangiogenic profile of conjunctival and uveal melanoma cell lines. Invest Ophthalmol Vis Sci 2015; 56: 5691-5697
    CrossrefPubMedGoogle Scholar
  • 25 Schlereth SL, Iden S, Mescher M. et al. A novel model of metastatic conjunctival melanoma in immune-competent mice. Invest Ophthalmol Vis Sci 2015; 56: 5965-5973
    CrossrefPubMedGoogle Scholar
  • 26 Schlereth SL, Neuser B, Caramoy A. et al. Enrichment of lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1)-positive macrophages around blood vessels in the normal human sclera. Invest Ophthalmol Vis Sci 2014; 55: 865-872
    CrossrefPubMedGoogle Scholar
  • 27 Schlereth SL, Kremers S, Schrödl F. et al. Characterization of antigen-presenting macrophages and dendritic cells in the healthy human sclera. Invest Ophthalmol Vis Sci 2016; 57: 4878-4885
    CrossrefPubMedGoogle Scholar
  • 28 Grajewski RS, Bosch JJ, Bruns H. et al. The Trojan horse tale revisited: an eye on metastatic spread of carcinoma cells. Cancer Immunol Res 2016; 4: 92-94
    CrossrefPubMedGoogle Scholar
  • 29 Bosch JJ, Thompson JA, Srivastava MK. et al. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells. Cancer Res 2007; 67: 4499-4506
    CrossrefPubMedGoogle Scholar
  • 30 Bosch JJ, Iheagwara UK, Reid S. et al. Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells. Cancer Immunol Immunother 2010; 59: 103-112
    CrossrefPubMedGoogle Scholar
  • 31 Franklin C, Livingstone E, Roesch A. et al. Immunotherapy in melanoma: Recent advances and future directions. Eur J Surg Oncol 2017; 43: 604-611
    CrossrefPubMedGoogle Scholar
  • 32 Griewank KG, Westekemper H, Murali R. et al. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Cancer Res 2013; 19: 3143-3152
    CrossrefPubMedGoogle Scholar
  • 33 Damato B, Coupland SE. Management of conjunctival melanoma. Expert Rev Anticancer Ther 2009; 9: 1227-1239
    CrossrefPubMedGoogle Scholar
  • 34 Heindl LM, Cursiefen C. Bindehautmelanom – eine Systemerkrankung. Ophthalmologe 2015; 112: 890-891
    CrossrefPubMedGoogle Scholar
  • 35 Bock F, Maruyama K, Regenfuss B. et al. Novel anti(lymph)angiogenic treatment strategies for corneal and ocular surface diseases. Prog Retin Eye Res 2013; 34: 89-124
    CrossrefPubMedGoogle Scholar
  • 36 Field MG, Harbour JW. Recent developments in prognostic and predictive testing in uveal melanoma. Curr Opin Ophthalmol 2014; 25: 234-239
    CrossrefPubMedGoogle Scholar
  • 37 Zimmer L, Vaubel J, Mohr P. et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma. PLoS One 2015; 10: e0118564
    CrossrefPubMedGoogle Scholar
  • 38 Algazi AP, Tsai KK, Shoushtari AN. et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer 2016; 122: 3344-3353
    CrossrefPubMedGoogle Scholar
  • 39 Bosch JJ. Immunotherapy of uveal melanoma. Dev Ophthalmol 2012; 49: 137-149
    PubMedGoogle Scholar
  • 40 Tschentscher F, Hüsing J, Hölter T. et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res 2003; 63: 2578-2584
    PubMedGoogle Scholar
  • 41 Onken MD, Ehlers JP, Worley LA. et al. Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. Cancer Res 2006; 66: 4602-4609
    CrossrefPubMedGoogle Scholar
  • 42 Schuler-Thurner B, Bartz-Schmidt KU, Bornfeld N. et al. Immunotherapy of uveal melanoma: vaccination against cancer. Multicenter adjuvant phase 3 vaccination study using dendritic cells laden with tumor RNA for large newly diagnosed uveal melanoma. Ophthalmologe 2015; 112: 1017-1021
    CrossrefPubMedGoogle Scholar
  • 43 Heindl LM, Koch KR, Schlaak M. et al. Adjuvante Therapie und interdisziplinäre Nachsorge des Bindehautmelanoms. Ophthalmologe 2015; 112: 907-911
    CrossrefPubMedGoogle Scholar